Abstract
4D Molecular Therapeutics has become the latest developer of a Fabry disease gene therapy to run into difficulties. After seeing (https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-updates-clinical-pipeline) three cases of a kidney condition in the first six patients, the biotech has decided to stop enrollment and collect more follow-up data before deciding on the next steps.
Key Data
-
Publication Date11 January 2023
-
Primary AuthorNick Paul Taylor
-
SourceFierce Biotech
-
LanguageEnglish
Click below to visit original source: